PD-1 Inhibitors-Related Neurological Toxicities in Patients with Non-Small-Cell Lung Cancer: A Literature Review
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PD-1 Inhibitors-Related Neurological Toxicities in Patients with Non-Small-Cell Lung Cancer: A Literature Review
Authors
Keywords
-
Journal
Cancers
Volume 11, Issue 3, Pages 296
Publisher
MDPI AG
Online
2019-03-04
DOI
10.3390/cancers11030296
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Development of Bell’s Palsy After Treatment With Ipilimumab and Nivolumab for Metastatic Melanoma
- (2018) Julia M. Zecchini et al. JOURNAL OF IMMUNOTHERAPY
- Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors
- (2017) D. Makarious et al. EUROPEAN JOURNAL OF CANCER
- Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature
- (2017) S. Cuzzubbo et al. EUROPEAN JOURNAL OF CANCER
- Myasthenia gravis induced by nivolumab in patients with non-small-cell lung cancer: a case report and literature review
- (2017) Yoshikazu Hasegawa et al. Immunotherapy
- Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors
- (2017) Sophie Feng et al. Journal of Thoracic Oncology
- Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan
- (2017) Shigeaki Suzuki et al. NEUROLOGY
- Neurological Complications Associated With Anti–Programmed Death 1 (PD-1) Antibodies
- (2017) Justin C. Kao et al. JAMA Neurology
- Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature
- (2016) L. Spain et al. ANNALS OF ONCOLOGY
- Neurologic complications of immune checkpoint inhibitors
- (2016) Andreas F. Hottinger CURRENT OPINION IN NEUROLOGY
- Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
- (2016) Lisa Zimmer et al. EUROPEAN JOURNAL OF CANCER
- Benign form of myasthenia gravis after nivolumab treatment
- (2016) Giorgia Sciacca et al. MUSCLE & NERVE
- Myasthenia gravis induced by nivolumab therapy in a patient with non-small-cell lung cancer
- (2016) Pinar Polat et al. MUSCLE & NERVE
- Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer
- (2016) Tanya J. Williams et al. JAMA Neurology
- Eosinophilic Fasciitis and Acute Encephalopathy Toxicity from Pembrolizumab Treatment of a Patient with Metastatic Melanoma
- (2016) L. Khoja et al. Cancer Immunology Research
- Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports
- (2016) Noha Abdel-Wahab et al. PLoS One
- Update on neurological paraneoplastic syndromes
- (2015) Romana Höftberger et al. CURRENT OPINION IN ONCOLOGY
- Bilateral Facial Palsy following Ipilimumab Infusion for Melanoma
- (2015) Ashley L. Altman et al. OTOLARYNGOLOGY-HEAD AND NECK SURGERY
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab
- (2013) Jeffrey S. Weber et al. CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More